Login to Your Account

Daiichi commits up to $650M to Charleston Labs for nausea drugs

By Michael Fitzhugh
Staff Writer

Thursday, August 7, 2014

Daiichi Sankyo Co. Ltd. is investing up to $650 million in a Charleston Laboratories Inc. subsidiary to back development and U.S. commercialization of its hydrocodone combination drug portfolio, including CL-108, a late-stage therapy providing the pain relief of hydrocodone without the common nausea and vomiting associated with the widely prescribed opioid.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription